5:21 PM
 | 
Nov 07, 2007
 |  BC Extra  |  Clinical News

Meditor's MTR106 meets migraine endpoint

Meditor (Rehovot, Israel) said all four doses of MTR106 met the primary endpoint of superiority to...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >